Log In
BCIQ
Print this Print this
 

Simponi Aria (IV Simponi golimumab)

  Manage Alerts
Collapse Summary General Information
Company Johnson & Johnson
DescriptionIV formulation of human mAb against tumor necrosis factor (TNF) alpha
Molecular Target Tumor necrosis factor (TNF) alpha
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentMarketed
Standard IndicationRheumatoid arthritis (RA)
Indication DetailsTreat moderate to severe rheumatoid arthritis (RA)
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$500.0M

$500.0M

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

05/05/2009

$500.0M

$500.0M

0

Get a free BioCentury trial today